A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD
Clinical trial NCT04632056 · COMPLETED
Trial details
- NCT number
- NCT04632056
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2020-11-16
- Primary completion
- 2022-11-10
- Enrollment
- 329
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.